Base de datos : IBECS
Búsqueda : "1699-048X" [ISSN]
Referencias encontradas : 2780 [refinar]
Mostrando: 1 .. 10   en el formato [Detallado]

página 1 de 278 va a la página                         

  1 / 2780 IBECS  
              next record last record
selecciona
para imprimir
Id: 230808
Autor: Pérez-Torres Lobato, Maria; Valero Arrese, Lorena; Llort Sales, Anna; Gros Subias, Luis; Moreno, Lucas; Navarro-Marchena, Lucía; de Noriega, Iñigo; Morey Olivé, Miriam; Solano-Páez, Palma; Márquez Vega, Catalina; Quiroga-Cantero, Eduardo.
Título: Palliative care for children with central nervous system tumors: results of a Spanish multicenter study
Fuente: Clin. transl. oncol. (Print);26(3):786-795, mar. 2024.
Idioma: en.
doi: 10.1007/s12094-023-03301-7.
Resumen: Background Brain tumors represent the most common cause of cancer-related death in children. Few studies concerning the palliative phase in children with brain tumors are available. Objectives (i) To describe the palliative phase in children with brain tumors; (ii) to determine whether the use of palliative sedation (PS) depends on the place of death, the age of the patient, or if they received specific palliative care (PC). Methods Retrospective multicenter study between 2010 and 2021, including children from one month to 18 years, who had died of a brain tumor. Results 228 patients (59.2% male) from 10 Spanish institutions were included. Median age at diagnosis was 5 years (IQR 2û9) and median age at death was 7 years (IQR 4û11). The most frequent tumors were medulloblastoma (25.4%) and diffuse intrinsic pontine glioma (DIPG) (24.1%). Median number of antineoplastic regimens were 2 (range 0û5 regimens). During palliative phase, 52.2% of the patients were attended by PC teams, while 47.8% were cared exclusively by pediatric oncology teams. Most common concerns included motor deficit (93.4%) and asthenia (87.5%) and communication disorders (89.8%). Most frequently prescribed supportive drugs were antiemetics (83.6%), opioids (81.6%), and dexamethasone (78.5%). PS was administered to 48.7% patients. Most of them died in the hospital (85.6%), while patients who died at home required PS less frequently (14.4%) (p = .01). Conclusion Children dying from CNS tumors have specific needs during palliative phase. The optimal indication of PS depended on the center experience although, in our series, it was also influenced by the place of death (AU)
Descriptores: neoplasias cerebrales/terapia
cuidados paliativos
-estudios retrospectivos
Límites: seres humanos
lactante
niño preescolar
niño
Tipo de Publicación: estudio multicéntrico
Responsable: ES15.1 - BNCS


  2 / 2780 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Texto Completo
Id: 230807
Autor: Rao, Hui; Zeng, Xiaoli; Wen, Xuejiao; Huang, Li; Wang, Qi.
Título: Analysis of the prognostic value of uric acid on the efficacy of immunotherapy in patients with primary liver cancer
Fuente: Clin. transl. oncol. (Print);26(3):774-785, mar. 2024. graf, ilus.
Idioma: en.
doi: 10.1007/s12094-023-03314-2.
Resumen: Purpose Uric acid (UA) plays a dual role as an antioxidant and a prooxidant in patients with malignant tumors; however, the relationship between serum UA and malignancy is currently unclear. This study aims to investigate the prognostic value of serum uric acid level before immunotherapy on the efficacy of primary liver cancer (PLC) immunotherapy, which might provide a basis for optimizing the comprehensive treatment scheme. Methods Patients with PLC who were admitted to the First Affiliated Hospital of Gannan Medical College from January 2019 to June 2022 and underwent immunotherapy were collected retrospectively. The difference between serum UA levels in patients with PLC, the correlation between serum UA levels, and the clinical characteristics of patients with PLC were analyzed using the chi-square test, and the survival was estimated using the KaplanûMeier analysis. To further assess the prognostic significance of UA concentrations, univariate and multivariate Cox regression analyses were performed. Results Ninety-nine patients were included in this study cohort. The median follow-up was 7 months (range: 1û29 months), and 76 (76.8%) of the 99 patients with PLC died as of December 31, 2022. Serum UA concentrations ranged from 105 to 670 μmol/l, with a median of 269 μmol/l. The results showed that the serum UA level of patients with PLC was higher than that of healthy subjects (P < 0.001). After subgroup analyses, only male patients with liver cancer had higher serum UA levels than healthy men (P = 0.001). The results of the KaplanûMeier analysis showed that higher UA levels were associated with poor overall survival (OS) (P = 0.005) (AU)
Descriptores: neoplasias hepáticas/terapia
neoplasias hepáticas/sangre
ácido úrico/sangre
inmunoterapia
-marcadores tumorales/sangre
estudios retrospectivos
pronóstico
Límites: seres humanos
masculino
Responsable: ES15.1 - BNCS


  3 / 2780 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 230806
Autor: Lai, Ming-Yu; Guan, Wen-Long; Yang, Jing; Sun, Yu-Ting; Qiu, Miao-Zhen; Lu, Shi-Xun; Yang, Li-Qiong; Yang, Da-Jun.
Título: The relationship between brain metastasis and HER2 expression status in gastric cancer
Fuente: Clin. transl. oncol. (Print);26(3):765-773, mar. 2024.
Idioma: en.
doi: 10.1007/s12094-023-03306-2.
Resumen: Background Brain metastasis (BM) in gastric cancer (GC) is underestimated, and human epidermal growth factor receptor 2 (HER2) overexpression is a durable poor prognostic factor. We explored the relationship between the two and made a survival analysis. Methods HER2 expression and BM status were collected from GC patients who were diagnosed between December 2009 and May 2021. We collected GC patients diagnosed between 2010 and 2016 from the SEER database. The primary endpoint was survival from the diagnosis of BM. Multivariable logistic regression was used to determine potential risk factors of BM at diagnosis in SEER database. Survival analysis was performed using the KaplanûMeier method. Result There were 513 HER2-positive GC patients, including 16 (3.1%) with BM. Among 38 brain metastasis GC patients we collected, 16 (42.1%) patients were HER2 positive. We collected 34,199 GC patients from the SEER database and there were 260 (0.76%) patients with BM at diagnosis. GC patients that are male, white, of younger age, with primary lesions located in the proximal stomach or with distant lymph nodes, liver, bone, or lung metastasis are more likely to develop BM. The median overall survival time from diagnosis of BM was 12.73 months, and the survival time from brain metastasis of HER2-positive patients was numerically shorter, though the difference was not significant (5.30 months vs.16.13 months, P = 0.28.) Conclusion The incidence of BM in patients with HER2-positive gastric cancer is 4.08 times higher than that in general patients. The median overall survival time from BM is shorter for HER2-positive patients (AU)
Descriptores: neoplasias cerebrales/secundario
neoplasias gástricas/patología
receptor ErbB-2/metabolismo
-análisis de supervivencia
factores de riesgo
pronóstico
Límites: seres humanos
masculino
femenino
Responsable: ES15.1 - BNCS


  4 / 2780 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 230805
Autor: Ji, Nan-Nan; Zeng, Yue-Can; Wu, Xiao-Wen; Cao, Qian; Li, Zhi-Hui; Liu, Rui; Tu, Wei.
Título: Influence of cancer-directed surgery on the prognosis of liver metastases from gastric cancer
Fuente: Clin. transl. oncol. (Print);26(3):756-764, mar. 2024.
Idioma: en.
doi: 10.1007/s12094-023-03305-3.
Resumen: There are controversial about the application of cancer-directed surgery (CDS) in patients with liver metastases from gastric cancer, with improved responses to chemotherapy and targeted treatments, the role of CDS in metastatic gastric cancer to the liver needs to be revisited. This study aimed to evaluate the effect of CDS on patients with liver metastases from gastric cancer. Data for patients with liver metastases from gastric cancer were extracted from the population-based Surveillance, Epidemiology, and End Results (SEER) database. A total of 958 individuals were enrolled, 285 in the CDS group and 673 in the non-cancer guided surgery (Non-CDS) group. Following propensity score matching (PSM) analysis at 1:1 in the two groups,285 were included in the survival analysis for each group. KaplanûMeier values and Cox proportional risk models were used to estimate the effect of CDS on patients' prognoses. Compared with the Non-CDS group, the CDS group significantly prolonged the median overall survival from 4 months (95% confidence interval [CI] 3û5) to 11 months (95% CI 8û12), p value < 0.001. Overall survival (OS) at 1 year was higher in the CDS group than in the Non-CDS group, at 44% (95 CI 38û50) and 25% (95 CI 20û30), respectively. OS at 3 years was also higher in the CDS group than in the Non-CDS group, at 24% (95 CI 19û29) and 6% (95 CI 3û9), respectively. Multivariate analysis showed that Non-CDS (hazard ratio[HR] = 2.26, 95% CI 1.88û2.72, p value < 0.001) was an adverse independent prognostic factor for patients (AU)
Descriptores: neoplasias hepáticas/secundario
neoplasias hepáticas/cirugía
neoplasias gástricas/patología
neoplasias gástricas/cirugía
-estudios retrospectivos
estudios prospectivos
calidad de vida
pronóstico
Límites: seres humanos
Responsable: ES15.1 - BNCS


  5 / 2780 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 230804
Autor: Liu, Lina; Shi, Zhongyi; Qiu, Xingdong.
Título: Impact of bone metastasis on the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
Fuente: Clin. transl. oncol. (Print);26(3):747-755, mar. 2024.
Idioma: en.
doi: 10.1007/s12094-023-03300-8.
Resumen: Background This review was implemented to examine the impact of bone metastasis on the prognosis of non-small cell lung cancer patients (NSCLC) treated with immune checkpoint inhibitors (ICIs). Methods A literature search was conducted in the PubMed, CENTRAL, Web of Science, and Embase databases up to 4th September 2022. Multivariable adjusted data were pooled in a random-effects model. Results 13 studies were included. On a combined analysis of 10 studies, it was noted that bony metastasis was associated with poor overall survival (OS) in NSCLC patients treated with ICIs (HR: 1.55 95% CI 1.24, 1.94 I2 = 69% p = 0.001). Meta-analysis of seven studies showed that bony metastasis was not associated with poor progression-free survival (PFS) in NSCLC patients treated with ICIs (HR: 1.31 95% CI 0.85, 2.01 I2 = 85% p = 0.22). Meta-regression analysis using the moderator's age, male gender, smoking history, squamous histology, and ICI as 1st line therapy for the outcome OS was not statistically significant. Conclusion The presence of bone metastasis is a predictor of poor OS in NSCLC treated with ICIs. However, PFS does not seem to be influenced by the presence of bone metastasis. Clinicians should prioritize the management of NSCLC patients with bone metastasis and explore the use of combination therapies to achieve optimal results. Further studies taking into account different combination therapies for such patients would strengthen the evidence (AU)
Descriptores: /uso terapéutico
INHIBIDORES DE PUNTOS DE CONTROL INMUNITARIO/uso terapéutico
neoplasias de tejido óseo/farmacoterapia
carcinoma de pulmón de células no pequeñas/farmacoterapia
neoplasias pulmonares/farmacoterapia
-pronóstico
Límites: seres humanos
masculino
Tipo de Publicación: metaanálisis
revisión sistemática
Responsable: ES15.1 - BNCS


  6 / 2780 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 230803
Autor: Li, Jielang; Huang, Chen; Wang, Xin; Li, Zhiping; Shen, Yali.
Título: Capecitabine/cisplatin combined with concurrent intensity-modulated radiation therapy: a feasible therapeutic strategy for anal squamous cell carcinoma
Fuente: Clin. transl. oncol. (Print);26(3):739-746, mar. 2024.
Idioma: en.
doi: 10.1007/s12094-023-03296-1.
Resumen: Purpose To evaluate the efficacy and safety of capecitabine/cisplatin (XP) combined with intensity-modulated radiation therapy (IMRT) in patients with non-metastatic anal squamous cell carcinoma (ASCC). Method and materials All patients with ASCC who received radical concurrent chemoradiotherapy in the past 8 years were screened. Patients who received XP or mitomycin/5-fluorouracil (MF) were selected and analyzed retrospectively. Results ASCC is an uncommon cancer, there were 36 patients were included in our study. The XP group and MF group included 18 patients each. The clinical complete response (cCR) rates in the XP group and the MF group were 94.4% and 88.9%, respectively (P = 1). The 2-year local control (LC), disease-free survival (DFS), and colostomy-free survival (CFS) rates were higher in the XP group than in the MF group (100% vs 93.3%, P = 0.32). Hematologic toxicities, especially grade ≥ 3 leukopenia (11.1% vs 44.4%, P = 0.06) and neutropenia (5.6% vs 61.1%, P = 0.001), were lower in the XP group than MF group. As a result of fewer side effects, fewer patients in the XP group demanded the dose reduction of chemotherapy (11.1% vs 50%, P = 0.03) and radiation interruption (55.6% vs 77.8%, P = 0.289). Delayed radiotherapy was shorter in the XP group (2.5 vs 6.5 days, P = 0.042) than in the MF group. Conclusion The XP regimen was as effective as the MF regimen in non-metastatic ASCC. Compared with the standard MF regimen, XP combined with IMRT showed higher treatment completion and lower toxicities. It could be considered a feasible alternative for patients with non-metastatic ASCC (AU)
Descriptores: neoplasias del ano/farmacoterapia
carcinoma de células escamosas/farmacoterapia
radioterapia de intensidad modulada
protocolos de quimioterapia antineoplásica combinada/uso terapéutico
capecitabina/uso terapéutico
cisplatino/uso terapéutico
radioterapia de intensidad modulada/métodos
-fluorouracilo/uso terapéutico
mitomicina/uso terapéutico
estudios retrospectivos
Límites: seres humanos
Responsable: ES15.1 - BNCS


  7 / 2780 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 230802
Autor: García-Donas, Jesús; Barba, María; Rodríguez-Moreno, Juan Francisco; Velasco, Guillermo de; Madurga, Rodrigo; Chamorro, Jesús; Rosero, Diana; Etxaniz, Olatz; Pérez-Gracia, Jose Luis; Pinto, Álvaro; Cacho, Diego.
Título: Caseûcontrol study assessing the impact of COVID19 in advanced kidney cancer patients treated with antiangiogenics or immunotherapy: the COVID-REN study
Fuente: Clin. transl. oncol. (Print);26(3):732-738, mar. 2024.
Idioma: en.
doi: 10.1007/s12094-023-03295-2.
Resumen: Background Cancer is a risk factor for developing severe COVID19. Additionally, SARS-CoV2 has a special tropism for renal cells and complications like thrombosis or cytokine storm could be enhanced by standard treatments in kidney cancer (i.e., antiangiogenics or immunotherapy). Thus, understanding the impact of COVID19 in patients with this tumor is key for their correct management. Methods We designed a retrospective caseûcontrol study comparing the outcome of three groups of advanced kidney cancer patients on systemic treatment: cohort A (developed COVID19 while on antiangiogenics), cohort B (developed COVID19 while on immunotherapy) and cohort C (non-infected). Matching factors were age, gender, and treatment. Results 95 patients were recruited in 16 centers in Spain from September 2020 to May 2021. Finally, 85 were deemed as eligible (23 cohort A, 21 cohort B, 41 cohort C). Patients with COVID required more dose interruptions (25 vs. six) and hospitalizations (10 vs. none) than those without COVID (both p = 0.001). No difference between cohorts A and B was observed regarding hospitalization or length of stay. No ICU admission was registered and one patient in cohort B died due to COVID19. Regarding cancer evolution, three patients in cohort A presented progressive disease after COVID19 compared to two in cohort B. One case in cohort B, initially deemed as stable disease, achieved a partial response after COVID19. Conclusions Kidney cancer patients who developed COVID19 while on systemic therapy required more treatment interruptions and hospitalizations than those non-infected. However, no significant impact on cancer outcome was observed. Also, no difference was seen between cases on antiangiogenics or immunotherapy (AU)
Descriptores: COVID-19
neoplasias renales/terapia
inmunoterapia
-estudios de casos y controles
estudios retrospectivos
ARN vírico
Límites: seres humanos
Responsable: ES15.1 - BNCS


  8 / 2780 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 230801
Autor: Du, Kai-Xin; Shen, Hao-Rui; Pan, Bi-Hui; Luthuli, Sibusiso; Wang, Li; Liang, Jin-Hua; Li, Yue; Yin, Hua; Li, Jian-Yong; Wu, Jia-Zhu.
Título: Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma
Fuente: Clin. transl. oncol. (Print);26(3):720-731, mar. 2024.
Idioma: en.
doi: 10.1007/s12094-023-03292-5.
Resumen: Purpose The International Extranodal Lymphoma Study Group (IELSG) score is widely used in clinical practice to stratify the risk of primary central nervous system lymphoma (PCNSL) patients. Our study aims to confirm and improve the IELSG score in PCNSL patients based on Chinese populations. Materials and methods A total of 79 PCNSL patients were retrospectively analyzed. All patients treated with high-dose methotrexate (HD-MTX)-based therapy collected clinical data. The receiver-operating characteristic (ROC) curve was used to determine the optimal cut-off values for the factors in IELSG score. Progression of disease (POD) at the most landmark time point was determine by Epanechnikov kernel and the area under the ROC curve (AUROC). KaplanûMeier and multivariable regression methods were used to analyze survival data. Nomogram was generated for calculating the weight of each selected factor. Results The traditional IELSG score had no significant difference on OS and PFS except ECOG ≥ 2 and could not stratify the risk groups in PCNSL. The improved IELSG scoring system was established, which incorporated age ≥ 54 years, ECOG ≥ 2, deep brain structure, elevated CSF protein, and LDH/ULN > 0.75. On the other hand, POD18 was identified as a new powerful prognostic factor for PCNSL. In multivariate analysis, POD18 and the improved IELSG scoring system were independent prognostic factors for OS. Nomogram including the two significant variables showed the best performance (C-index = 0.828). Conclusions In this study, the IELSG score was improved and a new prognostic indicator POD18 was incorporated to construct a nomogram prognostic model, thereby further improving the predictive ability of the model (AU)
Descriptores: linfoma compuesto/farmacoterapia
linfoma compuesto/metabolismo
metotrexato/uso terapéutico
-estudios retrospectivos
resultado del tratamiento
encéfalo/metabolismo
pronóstico
Límites: seres humanos
persona de mediana edad
Responsable: ES15.1 - BNCS


  9 / 2780 IBECS  
              first record previous record next record last record
selecciona
para imprimir
Id: 230800
Autor: Cheng, Debin; Liu, Dong; Mi, Zhenzhou; Zhang, Zhao; Tao, Weidong; Dang, Jingyi; Zhu, Dongze; Fu, Jun; Fan, Hongbin; Li, Xian.
Título: A deep learning model for accurately predicting cancer-specific survival in patients with primary bone sarcoma of the extremity: a population-based study
Fuente: Clin. transl. oncol. (Print);26(3):709-719, mar. 2024.
Idioma: en.
doi: 10.1007/s12094-023-03291-6.
Resumen: Purpose Primary bone and joint sarcomas of the long bone are relatively rare neoplasms with poor prognosis. An efficient clinical tool that can accurately predict patient prognosis is not available. The current study aimed to use deep learning algorithms to develop a prediction model for the prognosis of patients with long bone sarcoma. Methods Data of patients with long bone sarcoma in the extremities was collected from the Surveillance, Epidemiology, and End Results Program database from 2004 to 2014. Univariate and multivariate analyses were performed to select possible prediction features. DeepSurv, a deep learning model, was constructed for predicting cancer-specific survival rates. In addition, the classical cox proportional hazards model was established for comparison. The predictive accuracy of our models was assessed using the C-index, Integrated Brier Score, receiver operating characteristic curve, and calibration curve. Results Age, tumor extension, histological grade, tumor size, surgery, and distant metastasis were associated with cancer-specific survival in patients with long bone sarcoma. According to loss function values, our models converged successfully and effectively learned the survival data of the training cohort. Based on the C-index, area under the curve, calibration curve, and Integrated Brier Score, the deep learning model was more accurate and flexible in predicting survival rates than the cox proportional hazards model. Conclusion A deep learning model for predicting the survival probability of patients with long bone sarcoma was constructed and validated. It is more accurate and flexible in predicting prognosis than the classical CoxPH model (AU)
Descriptores: neoplasias de tejido óseo/secundario
aprendizaje profundo
nomogramas
osteosarcoma/patología
osteosarcoma/terapia
sarcoma/patología
-extremidades
pronóstico
Límites: seres humanos
Responsable: ES15.1 - BNCS


  10 / 2780 IBECS  
              first record previous record
selecciona
para imprimir
Id: 230799
Autor: Li, Xuejie; Yan, Shirong; Hu, Pei; Wang, Pingfeng; Gu, Jiangxue; Zhang, Yuan; Wu, Yuqin; Li, Ying.
Título: LncRNA XXYLT1-AS2 promotes tumor progression via autophagy inhibition through ubiquitinated degradation of TFEB in hepatocellular carcinoma
Fuente: Clin. transl. oncol. (Print);26(3):698-708, mar. 2024.
Idioma: en.
doi: 10.1007/s12094-023-03294-3.
Resumen: Purpose There is compelling evidence that long-stranded non-coding RNAs (lncRNAs) play an important role in the progression of hepatocellular carcinoma (HCC). The aim of this study was to investigate the role of lncRNA XXYLT1 antisense-2 (XXYLT1-AS2) in HCC progression. Methods Real-time PCR was used to assess the levels of XXYLT1-AS2 in plasma from HCC and normal patients. Cell proliferation, apoptosis, migration, and invasion were monitored, and tumor xenografts were established to investigate the biological functions of XXYLT1-AS2 by gain-of-function and loss-of-function studies in vitro and in vivo, the expression of autophagy biomarkers and transcriptional factor EB (TFEB) was examined by immunoprecipitation, ubiquitination assays, and western blotting. Autophagy inhibitor, 3-methyladenine (3MA), and proteasome inhibitor, MG132, were used to verify the role of autophagy in HCC progression and the effect of XXYLT1-AS2 on TFEB ubiquitination, respectively. Results In this study, we identified that lncRNA XXYLT1-AS2 is highly expressed in HCC plasma and promotes tumor growth in vivo. In functional studies, it was found that silent expression of XXYLT1-AS2 inhibited HCC proliferation, migration, invasion, and activated autophagy of HCC cells, which were attenuated by autophagy inhibitor, 3MA. Mechanistically, XXYLT1-AS2 decreased the protein level of TFEB through promoting its degradation by ubiquitin proteasome pathway. Conclusion XXYLT1-AS2 plays an oncogenic role in HCC progression through inhibition of autophagy via promoting the degradation of TFEB, and thus could be a novel target for HCC treatment (AU)
Descriptores: carcinoma hepatocelular/patología
neoplasias hepáticas/patología
microARN/genética
ARN largo no codificante/genética
ARN largo no codificante/metabolismo
autofagia/genética
-factores de transcripción con hélice-asa-hélice y cremallera de leucina básicos/genética
factores de transcripción con hélice-asa-hélice y cremallera de leucina básicos/metabolismo
línea celular tumoral
movimiento celular/genética
movimiento celular
Límites: seres humanos
Responsable: ES15.1 - BNCS



página 1 de 278 va a la página                         
   


Refinar la búsqueda
  Base de datos : IBECS Formulario avanzado   
Buscar por : Formulario libre    Formulario básico

    Buscar en el campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPS/OMS - Centro Latinoamericano y del Caribe de Información en Ciencias de la Salud